Madamswer
It would help with your credibility if you admitted to where you've gone wrong in your analysis.
For instance, shouting me down when I quite reasonably speculated that the FDA would ease up on clinical trials for stem cell therapies.
I was right.
You seem to be grasping at straws now, in order to try to find a negative in all these positives for MSB.
How can getting products to market early be seen as a negative? It takes some creative thinking to manage it.
Nobody said you weren't very smart btw, but you aren't necessarily fair or balanced in your analysis IMO, but the facts do tend to speak louder than your claims.
Timeframe for 2015, page-51
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |